Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,470 across all filing types
Latest filing 2025-09-23 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
北京双鹭药业股份有限公司非独立董事辞职暨选举职工代表董事的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a non-independent director and the election of a new employee representative director. It details changes in the company's board composition, including the resignation report and election results. There are no financial statements or performance data, and the content focuses on board/management changes. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication or certification, so it is not RPA or RNS.
2025-09-23 Chinese
北京双鹭药业股份有限公司关于高级管理人员减持股份预披露公告
Director's Dealing Classification · 100% confidence The document is a public announcement regarding a senior management person's plan to reduce their shareholding in the company. It details the shareholder's identity, the number of shares to be reduced, the method and timing of the reduction, and compliance with relevant regulations. There are no financial statements, earnings data, or report attachments. The content matches the definition of a Director's Dealing report, which covers personal share transactions by company directors and executives (insider trades). The document length is short and focused solely on the share reduction plan by a senior manager, confirming it is not a full financial report or other type of filing.
2025-09-17 Chinese
北京市君泽君律师事务所关于北京双鹭药业股份有限公司2025年第一次临时股东会的法律意见
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the legality and validity of the procedures, attendance, and resolutions of the 2025 first extraordinary shareholders' meeting of Beijing Shuanglu Pharmaceutical Co., Ltd. It details the convening, attendance, voting procedures, and results of the shareholders' meeting, confirming compliance with relevant laws and company rules. The document does not contain financial statements or financial performance data but focuses on the legal validation of the shareholders' meeting and its resolutions. This type of document is a legal opinion related to a shareholders' meeting, which fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports on the voting results and legitimacy of the meeting's decisions.
2025-09-12 Chinese
北京双鹭药业股份有限公司2025年第一次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the resolutions passed at the 2025 first extraordinary shareholders meeting of Beijing Shuanglu Pharmaceutical Co., Ltd. It details the meeting convening, attendance, voting results on various proposals including amendments to the company articles and governance rules, and includes a legal opinion on the meeting's validity. The document is a formal disclosure of voting results from a shareholders meeting, not the meeting materials themselves or a full report. It fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (6714 characters) and content confirm it is a detailed voting results announcement rather than a brief report publication or a full report.
2025-09-12 Chinese
北京双鹭药业股份有限公司信息披露管理制度
Governance Information Classification · 95% confidence The document is titled '信息披露管理制度' (Information Disclosure Management System) and is a detailed internal policy document of Beijing SL Pharmaceutical Co., Ltd. It outlines the company's procedures, responsibilities, and legal compliance requirements for information disclosure, including definitions, internal controls, reporting obligations, and communication with regulatory bodies and investors. It references various types of reports (annual, interim, quarterly, temporary reports) and regulatory rules but does not itself contain any financial data, audit results, or actual report content. It is a governance and compliance manual rather than a financial report or announcement. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-08-25 Chinese
北京双鹭药业股份有限公司关联交易管理制度
Governance Information Classification · 95% confidence The document is titled '关联交易管理制度' which translates to 'Related Party Transaction Management System' and is a detailed internal policy document of Beijing Shuanglu Pharmaceutical Co., Ltd. It outlines definitions, management, approval procedures, disclosure requirements, and governance related to related party transactions. It is a corporate governance and compliance document rather than a financial report or announcement. It does not contain financial statements, earnings data, or audit results. It is not an announcement of a report but a governance policy document. Therefore, the most appropriate classification is Governance Information (CGR). The document length (9402 characters) supports it being a full policy document rather than a brief announcement or certification.
2025-08-25 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.